WestHill Financial Advisors’s Nurix Therapeutics NRIX Stock Holding History

WestHill Financial Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.3M	Sell	218,333 -10,000	-4%	-$170K	0.9%	16
2026 Q1	$3.54M	Hold	228,333	–	–	0.68%	17
2025 Q4	$4.33M	Hold	228,333	–	–	0.82%	16
2025 Q3	$2.11M	Hold	228,333	–	–	0.41%	19
2025 Q2	$2.6M	Hold	228,333	–	–	0.55%	19
2025 Q1	$2.71M	Hold	228,333	–	–	0.62%	18
2024 Q4	$4.3M	Sell	228,333 -10,000	-4%	-$229K	0.96%	16
2024 Q3	$5.36M	Sell	238,333 -45,000	-16%	-$1.02M	1.2%	16
2024 Q2	$5.91M	Hold	283,333	–	–	1.43%	15
2024 Q1	$4.16M	Hold	283,333	–	–	1.02%	16
2023 Q4	$2.92M	Hold	283,333	–	–	0.78%	17
2023 Q3	$2.23M	Hold	283,333	–	–	0.65%	18
2023 Q2	$2.83M	Hold	283,333	–	–	0.8%	17
2023 Q1	$2.52M	Hold	283,333	–	–	0.75%	17
2022 Q4	$3.11M	Hold	283,333	–	–	0.99%	16
2022 Q3	$3.69M	Hold	283,333	–	–	1.26%	16
2022 Q2	$3.59M	Hold	283,333	–	–	1.19%	16
2022 Q1	$3.97M	Hold	283,333	–	–	1.14%	16
2021 Q4	$8.2M	Hold	283,333	–	–	2.32%	11
2021 Q3	$8.49M	Buy	+283,333	New	+$8.74M	2.62%	10
2021 Q1	$8.81M	Buy	+283,333	New	+$10.7M	3.13%	9

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

WestHill Financial Advisors's NRIX Position: Q2 2026 in Review

WestHill Financial Advisors reduced its Nurix Therapeutics (NRIX) stake by 4.4% in Q2 2026, selling an estimated $170K and leaving 218,333 shares worth $5.3M. The position accounts for 0.9% of the portfolio, ranked #16.

WestHill Financial Advisors first reported a position in NRIX in Q1 2021 and has held it in 21 quarters since. The position peaked at $8.81M in Q1 2021. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

WestHill Financial Advisors held 218,333 shares of Nurix Therapeutics worth $5.3M as of Q2 2026.
WestHill Financial Advisors sold 10,000 Nurix Therapeutics shares in Q2 2026, an estimated $170K.
Nurix Therapeutics made up 0.9% of WestHill Financial Advisors's portfolio in Q2 2026, its #16 holding.
WestHill Financial Advisors first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 21 quarters since.
WestHill Financial Advisors's Nurix Therapeutics position peaked at $8.81M in Q1 2021.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on WestHill Financial Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.